53.49

1.12% 0.79

Exact Sciences Corp (EXAS)

Overview News Price History Option Chain Financials Discussions Forecast

Exact Sciences Corp stock is traded at $53.49, with a volume of 536.04K. It is up +1.12% in the last 24 hours and down -23.30% over the past month. Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Previous Close:

$52.70

Open:

$52.77

24h Volume:

536.04K

Relative Volume:

0.21

Market Cap:

$9.71B

Revenue:

$2.69B

Net Income/Loss:

$-214.04M

P/E Ratio:

-33.73

EPS:

-1.5857

Net Cash Flow:

$98.43M

1W Performance:

+4.64%

1M Performance:

-23.30%

6M Performance:

-0.43%

1Y Performance:

-18.19%

1-Day Range:

$52.17

$54.02

1-Week Range:

$48.72

$54.55

52-Week Range:

$40.62

$79.62

Exact Sciences Corp Stock (EXAS) Company Profile

Name

Exact Sciences Corp

Sector

Healthcare (1195)

Industry

Diagnostics & Research (57)

Phone

608-284-5700

Address

5505 ENDEAVOR LANE, MADISON, WI

Employee

6,600

Twitter

@exactsciences

Next Earnings Date

2024-11-05

Latest SEC Filings

EXAS's Discussions on Twitter

Compare EXAS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EXAS	53.45	9.71B	2.69B	-214.04M	98.43M	-1.5857
TMO	510.88	196.16B	42.37B	6.14B	7.78B	15.26
DHR	231.59	167.14B	23.74B	3.89B	4.98B	7.93
A	131.15	36.94B	6.50B	1.41B	1.42B	3.82
IQV	195.25	35.03B	15.32B	1.41B	1.96B	5.95
IDXX	413.08	33.80B	3.84B	866.24M	792.60M	9.80

Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-27-24	Initiated	Scotiabank	Sector Outperform
Jun-03-24	Resumed	Jefferies	Buy
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Sep-28-23	Initiated	Bernstein	Outperform
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy
May-05-23	Initiated	UBS	Neutral
Mar-09-23	Upgrade	Citigroup	Neutral → Buy
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Nov-03-21	Downgrade	Raymond James	Strong Buy → Outperform
Jul-29-21	Reiterated	BTIG Research	Buy
Jul-29-21	Reiterated	Canaccord Genuity	Buy
Jul-29-21	Reiterated	Oppenheimer	Outperform
Jul-29-21	Reiterated	Stifel	Buy
Jun-15-21	Initiated	Raymond James	Strong Buy
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Equal Weight
Jan-28-21	Initiated	Truist	Buy
Oct-29-20	Downgrade	UBS	Buy → Neutral
Oct-28-20	Downgrade	Citigroup	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Apr-02-20	Initiated	Evercore ISI	Outperform
Jan-10-20	Resumed	BTIG Research	Buy
Jan-07-20	Initiated	Citigroup	Buy
Dec-13-19	Initiated	Dougherty & Company	Buy
Nov-15-19	Initiated	Stifel	Buy
Oct-17-19	Reiterated	BofA/Merrill	Buy
Oct-01-19	Resumed	Craig Hallum	Buy
Sep-26-19	Initiated	Oppenheimer	Outperform
Feb-26-19	Upgrade	Goldman	Neutral → Buy
Oct-09-18	Initiated	UBS	Buy
Sep-05-18	Resumed	The Benchmark Company	Hold
Aug-13-18	Reiterated	Canaccord Genuity	Buy
Apr-03-18	Upgrade	BTIG Research	Neutral → Buy
Jan-29-18	Initiated	Goldman	Neutral
Jan-08-18	Reiterated	The Benchmark Company	Buy
Nov-13-17	Downgrade	Robert W. Baird	Outperform → Neutral
Nov-01-17	Downgrade	BTIG Research	Buy → Neutral

View All

Exact Sciences Corp Stock (EXAS) Latest News

04:09 AM

Swiss National Bank Increases Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

04:09 AM

Nov 20, 2024

Madison-based Exact Sciences reports Q3 results short of analysts’ expectations - Chippewa Herald

Nov 20, 2024

EULAV Asset Management Has $20.78 Million Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Nov 20, 2024

Nov 19, 2024

Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now - Insider Monkey

Nov 19, 2024

Exact Sciences Co. (NASDAQ:EXAS) Sees Large Drop in Short Interest - MarketBeat

Nov 19, 2024

Exact Sciences Co. (NASDAQ:EXAS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Nov 19, 2024

Nov 18, 2024

Exact Sciences Partners with Actor and TV Personality Carlos Ponce to Increase Awareness of Colon Cancer Screening Among Hispanic Community - Business Wire

Nov 18, 2024

EXAS Stock Set to Benefit From Favorable Study Data Backing MCED Test - Yahoo Finance

Nov 18, 2024

Nov 16, 2024

Chairman of The Board & CEO of Exact Sciences Picks Up 2.7% More Stock - Yahoo Finance

Nov 16, 2024

Nov 15, 2024

Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Simplify Asset Management Inc. - MarketBeat

Nov 15, 2024

Exact Sciences showcases early cancer detection test data at AACR meeting - Clinical Trials Arena

Nov 15, 2024

Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat

Nov 15, 2024

Nov 14, 2024

Exact Sciences Unveils Data Showing Promise of Multi-Cancer Early Detection at AACR Special Conference on Liquid Biopsy - BioSpace

Nov 14, 2024

Nov 13, 2024

Capital World Investors Reduces Stake in Exact Sciences Corp - GuruFocus.com

Nov 13, 2024

Exact Sciences CEO Kevin Conroy buys $1 million in stock By Investing.com - Investing.com Nigeria

Nov 13, 2024

Exact Sciences reports progress in early cancer detection - Investing.com

Nov 13, 2024

Exact Sciences reports progress in early cancer detection By Investing.com - Investing.com UK

Nov 13, 2024

Exact Sciences CEO Kevin Conroy buys $1 million in stock - Investing.com India

Nov 13, 2024

Exact Sciences' Cancer Test Shows 28% Better Early Detection, Could Cut Deaths by 17% | EXAS Stock News - StockTitan

Nov 13, 2024

Los Angeles Capital Management LLC Takes Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Nov 13, 2024

Nov 12, 2024